Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
23.84
-1.71 (-6.69%)
At close: Jan 9, 2026, 4:00 PM EST
23.90
+0.06 (0.25%)
After-hours: Jan 9, 2026, 7:57 PM EST
Capricor Therapeutics Revenue
Capricor Therapeutics had revenue of $11.13M in the twelve months ending September 30, 2025, down -52.08% year-over-year. In the year 2024, Capricor Therapeutics had annual revenue of $22.27M, down -11.55%.
Revenue (ttm)
$11.13M
Revenue Growth
-52.08%
P/S Ratio
97.26
Revenue / Employee
$69,566
Employees
160
Market Cap
1.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22.27M | -2.91M | -11.55% |
| Dec 31, 2023 | 25.18M | 22.63M | 886.81% |
| Dec 31, 2022 | 2.55M | 2.31M | 941.85% |
| Dec 31, 2021 | 244.90K | -65.35K | -21.06% |
| Dec 31, 2020 | 310.25K | -694.78K | -69.13% |
| Dec 31, 2019 | 1.01M | -666.33K | -39.87% |
| Dec 31, 2018 | 1.67M | -994.98K | -37.32% |
| Dec 31, 2017 | 2.67M | -1.33M | -33.32% |
| Dec 31, 2016 | 4.00M | -1.52M | -27.53% |
| Dec 31, 2015 | 5.52M | 730.95K | 15.27% |
| Dec 31, 2014 | 4.79M | 4.28M | 851.19% |
| Dec 31, 2013 | 503.23K | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 1.35M | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CAPR News
- 23 days ago - Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript - Seeking Alpha
- 4 weeks ago - Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel - Seeking Alpha
- 4 weeks ago - Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript - Seeking Alpha
- 5 weeks ago - Capricor Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 5 weeks ago - Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say - Benzinga
- 5 weeks ago - Capricor Therapeutics Duchenne Treatment Shows Strong Heart And Muscle Results In Trial - Benzinga
- 5 weeks ago - Capricor's muscle disorder cell therapy succeeds in late-stage study - Reuters
- 6 weeks ago - Martin Shkreli Takes Aim At Capricor — Stock Sinks - Benzinga